The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression.
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Loxo; Takeda; Theravance
Research Funding - Adaptimmune (Inst); ARIAD; AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Affymetrix
 
Hira Rizvi
No Relationships to Disclose
 
Elizabeth Jimenez Aguilar
No Relationships to Disclose
 
Meghan Mooradian
No Relationships to Disclose
 
Christine A. Lydon
No Relationships to Disclose
 
Danyon Anderson
No Relationships to Disclose
 
Megan Tenet
No Relationships to Disclose
 
Jennifer L. Sauter
Stock and Other Ownership Interests - Merck; Thermo Fisher Scientific
 
Mari Mino-Kenudson
Consulting or Advisory Role - H3 Biomedicine; Merrimack
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - Novartis; Pfizer; Roche/Genentech
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; Syndax
Research Funding - Bristol-Myers Squibb
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb